Form 4: ALX Oncology Director Boosts Stake via Pre-Planned Purchase

Corey S. Goodman, a Director and 10% owner of ALX Oncology Holdings Inc., acquired over 3.18 million shares of common stock through a pre-planned transaction.

Summary

• Corey S. Goodman, a Director and 10% owner of ALX Oncology Holdings Inc. (ALXO), acquired 3,184,713 shares of common stock.
• The transaction occurred on February 2, 2026, at a price of $1.57 per share.
• This acquisition was made pursuant to a Rule 10b5-1(c) pre-planned contract, instruction, or written plan for the purchase of equity securities.
• Following this transaction, Mr. Goodman's total indirect beneficial ownership in ALX Oncology Holdings Inc. amounts to 13,051,008 shares of common stock.
• These shares are held indirectly through various entities including venBio Global Strategic Fund II, L.P. (8,453,038 shares), venBio Global Strategic Fund, L.P. (3,969,789 shares), venBio SPV, LLC (461,811 shares), the Goodman Barinaga Trust (113,287 shares), and Emaldi Corporation (54,083 shares).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal. A substantial insider purchase by a director and 10% owner, especially under a Rule 10b5-1 plan, typically reflects high confidence in the company's future.

Positives

• A Director and 10% owner acquiring a significant number of shares (3,184,713) signals strong insider confidence in the company's future prospects.
• The purchase being executed under a Rule 10b5-1 plan indicates a pre-meditated investment decision, often based on a long-term view of the company's value.

Future Outlook

The acquisition of shares by a Director and 10% owner, particularly through a Rule 10b5-1 plan, suggests a positive long-term outlook for ALX Oncology Holdings Inc. from an insider's perspective.

Industry Context

StockSavvy.ai notes that insider purchases, especially by significant stakeholders like a 10% owner and director, often signal management's belief in the company's future prospects. When executed under a Rule 10b5-1 plan, these trades are pre-scheduled, indicating a strategic, rather than reactive, investment decision, which can be viewed favorably by the market.

Comparison to Industry Standards

• Insider buying by a director and 10% owner is generally considered a strong positive signal, often outperforming general market sentiment.
• Compared to typical insider transactions, a purchase of over 3 million shares represents a substantial investment, reinforcing the conviction of a key insider in ALX Oncology's valuation and future growth.

Related Party Transactions

• Corey S. Goodman's beneficial ownership is primarily indirect, held through entities where he serves in a leadership capacity (e.g., director of venBio Global Strategic GP II, Ltd., venBio Global Strategic GP, Ltd., managing director of venBio SPV, LLC, trustee for Goodman Barinaga Trust, and director for Emaldi Corporation). This structure highlights the related-party nature of his significant stake in ALX Oncology Holdings Inc.

Stakeholder Impact

• Shareholders may interpret this significant insider purchase as a positive indicator of the company's future prospects, potentially boosting investor confidence.
• The transaction reinforces the alignment of interests between a key insider and other shareholders.

Key Dates

Recommendation

A seasoned investor or institution would likely view this significant insider purchase by a Director and 10% owner as a strong 'buy' signal. Such a substantial investment, particularly when pre-planned under a Rule 10b5-1 plan, indicates deep conviction in the company's long-term value and future performance from someone with intimate knowledge of the business. This often precedes positive developments or reflects a belief that the stock is undervalued.

Keywords

ALX Oncology, ALXO, Corey S. Goodman, Insider Trading, Form 4, Stock Purchase, Beneficial Ownership, Director, 10% Owner, venBio, Rule 10b5-1